EOFY Banner (3)

We aim to push through these challenging times and raise $300,000 to continue to invest in the Control NETs clinical trial and our other key projects in 2020 and beyond...

Despite the increase in Australians being diagnosed with a Neuroendocrine Tumour (NETs), the Neuroendocrine Cancer community of dedicated researchers and clinicians receives limited assistance from the government to fund much needed clinical trials and research

With the recent stimulus packages that were announced to combat COVID-19, all government funding for medical research and not-for-profit charities will dramatically reduce and in some areas cease to exist. Although we face tough times ahead, as an organisation we have always been able to perform on the “smell of an oily rag”, and with your help this will continue.

Every dollar donated helps fund vital NET research and clinical trials.

CONTROL NETs Clinical Trial


Thanks to our donors $650,000 in funding was contributed to the Control NETs trial. 


Thanks to our donors, 75 Australian neuroendocrine cancer patients were able to participate in the trial.

NeuroEndocrine Cancer Australia with the help of Tour De Cure and Perpetual, proudly provided over $650,000 in funding for the vital CONTROL NETs clinical trial for the treatment of 75 Australian patients. These may not seem like big numbers, but they represent men and women with families and friends who have minimal treatment options.

With a staggering 85% of clinical trials delayed or even cancelled due to an inability to recruit enough patients, and with Phase II trials usually costing millions and years to complete, we are incredibly proud to see the success of this trial and grateful to the determination of the investigators and those patients who participated.

CONTROL NETs has been recognised globally as “practice changing”, looking to compare two treatment options, CAPTEM (chemotherapy) and PRRT (Lutate treatment) used individually or in combination, to guide better treatment care for NET patients.

Preliminary results have been presented at American Society of Clinical Oncology (ASCO) Gastro-Intestinal (GI) meeting 2020, European Neuroendocrine Tumour Society (ENETs) 2020 and last weekends ASCO 2020.

Preliminary findings of this trial have found:

  • Progression Free Survival (PFS) is superior in both arms (CAPTEM/PRRT & PRRT) than initial estimates (90% & 92%)
  • The trial has achieved better than expected results for patients extending their life with little side effects
  • As patients responded better than expected, PI Prof Nick Pavlakis and the CONTROL NETs investigators would like to extend the time observing patients on the trial, to gather more data for future trials such as a Phase III trial.

All donations made over $2 are tax deductible.

Michael's Story

“When I was placed into the clinical research study Control NETs… I was elated and unbelievably and eternally grateful to NeuroEndocrine Cancer Australia for making this possible.”

Michael Doyle

Michael was diagnosed with neuroendocrine cancer in 2015 and became a Control NETs participant in October 2016.
Michael is one of the 75 Australian NETs patients we were able to offer the Control NETs trial to. 
This trial has led to vital research around NETs treatment and wouldn’t have been possible without the generous contributions of our donors.
Michael’s full NETs story can be read here.

Help us hit our target of $300,000 to contribute to NET research and clinical trials.

Without your support NeuroEndocrine Cancer Australia isn’t able to continue to invest in the world first research that continues to improve the lives of Australian’s living with neuroendocrine cancer, like Michael.
Your continued support at this time is greatly appreciated. All donations received are fully tax deductible.
Thank you for helping improve the lives of neuroendocrine cancer patients.

Look how far our donations go

Over the last 12 months, NeuroEndocrine Cancer Australia has allocated all donations received to helping support the 5 pillars that our organisation are based on: support, education, research, awareness and advocacy, 

  • Answered over 150 patient calls per month.
  • Hosted over 90 face to face support groups.
  • In response to Covid-19, maintained support groups online.
  • Managed and facilitated private Facebook groups for 1100 members.
  • Presented 6 scientific abstracts at ENETs 2020.
  • Commenced development of INFO4NETs - an online tool that can be used to source information resources about Neuroendocrine Tumours.
  • Developed GP training modules to roll out a National GP training program.
  • Journal Publications
  • Fully funded the CONTROL NETs clinical trial allowing 75 patients to access life prolonging treatment.
  • Provided grants to Australian clinicians and researchers to enhance expertise in NET management.
  • Sponsor and launched the only Neuroendocrine Tumour Registry (PLaNET) currently with ethics approval in five states.
  • Rebrand to raise awareness around neuroendocrine tumours.
  • World NET Cancer Day - distributed 15,000 branded coffee sleeves, reached almost 2 millions listeners on National radio
  • 10 year anniversary, raising over $80,000
  • Let's Walk for NETs united patients, clinicians and the public through Covid-19 and reached almost 3 million viewers on Ticker TV
  • Currently lobbying for the implementation and funding for an Optimal Care Pathway.
  • NeuroEndocrine Cancer Australia Consumer Advisory Group (CAG), helping to improve outcomes for NET Cancer patients.
  • Coordination of patient submissions for drug access on the Pharmaceutical Benefits Scheme.

Every dollar received helps to improve the lives of Australians living with NETs.